TherapeuticsMD (TXMD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

TXMD Stock Forecast

TherapeuticsMD stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

TXMD Analyst Ratings

Buy

According to 1 Wall Street analysts, TherapeuticsMD's rating consensus is 'Buy'. The analyst rating breakdown for TXMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Mar 15, 2022	Cantor Fitzgerald	Overweight	Overweight	Hold

TherapeuticsMD's last stock rating was published by Cantor Fitzgerald on Mar 15, 2022. The company gave TXMD a "Overweight" rating, the same as its previous rate.

TherapeuticsMD Financial Forecast

TherapeuticsMD Revenue Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
Revenue	-	-	-	-	-	$-53.00K	-	$416.00K	$1.15M	$20.92M	$28.56M	$19.33M	$18.68M	$25.41M	$23.00M	$19.87M	$22.58M	$19.34M	$10.70M	$12.25M	$15.90M	$23.72M	$6.08M	$3.95M	$3.77M	$3.99M	$4.93M	$4.48M	$2.83M	$1.54M
Avg Forecast	$2.30M	$2.30M	$2.20M	$2.20M	$600.00K	$500.00K	$500.00K	$1.70M	$26.80M	$23.20M	$17.95M	$29.39M	$25.87M	$22.11M	$19.77M	$21.14M	$15.47M	$10.38M	$11.38M	$12.82M	$8.13M	$5.12M	$5.96M	$4.19M	$3.43M	$3.99M	$4.03M	$3.45M	$2.83M	$1.28M
High Forecast	$2.30M	$2.30M	$2.20M	$2.20M	$600.00K	$500.00K	$500.00K	$1.70M	$26.80M	$23.20M	$17.95M	$29.39M	$25.87M	$22.11M	$19.77M	$21.14M	$15.47M	$10.38M	$11.38M	$12.82M	$8.13M	$5.12M	$5.96M	$5.03M	$4.11M	$4.79M	$4.84M	$4.14M	$3.40M	$1.54M
Low Forecast	$2.30M	$2.30M	$2.20M	$2.20M	$600.00K	$500.00K	$500.00K	$1.70M	$26.80M	$23.20M	$17.95M	$29.39M	$25.87M	$22.11M	$19.77M	$21.14M	$15.47M	$10.38M	$11.38M	$12.82M	$8.13M	$5.12M	$5.96M	$3.35M	$2.74M	$3.19M	$3.23M	$2.76M	$2.26M	$1.03M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	9	9	9	9	5	5	5	12	10	7	11	13	12	10
Surprise %	-	-	-	-	-	-0.11%	-	0.24%	0.04%	0.90%	1.59%	0.66%	0.72%	1.15%	1.16%	0.94%	1.46%	1.86%	0.94%	0.96%	1.96%	4.63%	1.02%	0.94%	1.10%	1.00%	1.22%	1.30%	1.00%	1.20%

TherapeuticsMD's average Quarter revenue forecast for Dec 23 based on 1 analysts is $600.00K, with a low forecast of $600.00K, and a high forecast of $600.00K. TXMD's average Quarter revenue forecast represents a -1232.08% decrease compared to the company's last Quarter revenue of $-53.00K (Sep 23).

TherapeuticsMD EBITDA Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	9	9	9	9	5	5	5	12	10	7	11	13	12	10
EBITDA	-	-	-	-	-	$-1.28M	-	$-2.23M	$109.59M	$-25.86M	$-25.73M	$-34.18M	$-34.38M	$-40.35M	$-34.01M	$-28.14M	$-33.45M	$-23.91M	$-43.94M	$-49.58M	$-42.76M	$-26.21M	$-51.09M	$-37.31M	$-24.34M	$-21.11M	$-20.91M	$-20.88M	$-8.91M	$-4.94M
Avg Forecast	$-1.72M	$-1.72M	$-1.64M	$-40.57M	$-448.10K	$-373.41K	$-373.41K	$-36.88M	$-59.50M	$-17.15M	$-13.27M	$-33.53M	$-19.12M	$-16.34M	$-14.61M	$-30.48M	$-11.43M	$-7.67M	$-8.41M	$-44.36M	$-6.01M	$-3.78M	$-4.41M	$-39.50M	$-21.91M	$-21.11M	$-16.26M	$-14.62M	$-8.91M	$-3.95M
High Forecast	$-1.72M	$-1.72M	$-1.64M	$-32.46M	$-448.10K	$-373.41K	$-373.41K	$-29.51M	$-47.60M	$-17.15M	$-13.27M	$-26.82M	$-19.12M	$-16.34M	$-14.61M	$-24.39M	$-11.43M	$-7.67M	$-8.41M	$-35.49M	$-6.01M	$-3.78M	$-4.41M	$-31.60M	$-17.53M	$-16.89M	$-13.01M	$-11.69M	$-7.13M	$-3.16M
Low Forecast	$-1.72M	$-1.72M	$-1.64M	$-48.69M	$-448.10K	$-373.41K	$-373.41K	$-44.26M	$-71.40M	$-17.15M	$-13.27M	$-40.24M	$-19.12M	$-16.34M	$-14.61M	$-36.58M	$-11.43M	$-7.67M	$-8.41M	$-53.23M	$-6.01M	$-3.78M	$-4.41M	$-47.40M	$-26.29M	$-25.33M	$-19.52M	$-17.54M	$-10.69M	$-4.74M
Surprise %	-	-	-	-	-	3.44%	-	0.06%	-1.84%	1.51%	1.94%	1.02%	1.80%	2.47%	2.33%	0.92%	2.93%	3.12%	5.22%	1.12%	7.12%	6.93%	11.60%	0.94%	1.11%	1.00%	1.29%	1.43%	1.00%	1.25%

1 analysts predict TXMD's average Quarter EBITDA for Mar 23 to be $-36.88M, with a high of $-29.51M and a low of $-44.26M. This is -133.66% lower than TherapeuticsMD's previous annual EBITDA (Dec 22) of $109.59M.

TherapeuticsMD Net Income Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	9	9	9	9	5	5	5	12	10	7	11	13	12	10
Net Income	-	-	-	-	-	$-3.38M	-	$-3.60M	$-33.22M	$-28.96M	$112.28M	$-71.81M	$-50.54M	$-47.42M	$-42.65M	$-39.38M	$-42.09M	$-32.61M	$-51.98M	$-56.85M	$-49.44M	$-31.97M	$-55.24M	$-39.51M	$-24.40M	$-21.16M	$-20.93M	$-20.89M	$-9.18M	$-6.38M
Avg Forecast	$461.28K	$461.28K	$345.96K	$-56.79M	$-1.50M	$-1.73M	$-807.24K	$-51.62M	$-68.79M	$-35.06M	$-46.13M	$-46.93M	$-57.66M	$-63.43M	$-70.63M	$-42.66M	$-77.43M	$-95.86M	$-109.63M	$-50.86M	$-108.59M	$-99.67M	$-96.10M	$-41.83M	$-21.96M	$-21.16M	$-16.28M	$-14.63M	$-9.18M	$-5.10M
High Forecast	$461.28K	$461.28K	$345.96K	$-45.43M	$-1.50M	$-1.73M	$-807.24K	$-41.30M	$-55.03M	$-35.06M	$-46.13M	$-37.55M	$-57.66M	$-63.43M	$-70.63M	$-34.13M	$-77.43M	$-95.86M	$-109.63M	$-40.69M	$-108.59M	$-99.67M	$-96.10M	$-33.46M	$-17.57M	$-16.93M	$-13.02M	$-11.70M	$-7.35M	$-4.08M
Low Forecast	$461.28K	$461.28K	$345.96K	$-68.14M	$-1.50M	$-1.73M	$-807.24K	$-61.95M	$-82.55M	$-35.06M	$-46.13M	$-56.32M	$-57.66M	$-63.43M	$-70.63M	$-51.20M	$-77.43M	$-95.86M	$-109.63M	$-61.04M	$-108.59M	$-99.67M	$-96.10M	$-50.20M	$-26.35M	$-25.39M	$-19.53M	$-17.55M	$-11.02M	$-6.12M
Surprise %	-	-	-	-	-	1.95%	-	0.07%	0.48%	0.83%	-2.43%	1.53%	0.88%	0.75%	0.60%	0.92%	0.54%	0.34%	0.47%	1.12%	0.46%	0.32%	0.57%	0.94%	1.11%	1.00%	1.29%	1.43%	1.00%	1.25%

TherapeuticsMD's average Quarter net income forecast for Sep 22 is $-35.06M, with a range of $-35.06M to $-35.06M. TXMD's average Quarter net income forecast represents a -131.22% decrease compared to the company's last Quarter net income of $112.28M (Jun 22).

TherapeuticsMD SG&A Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	9	9	9	9	5	5	5	12	10	7	11	13	12	10
SG&A	-	-	-	-	-	$1.59M	-	$3.06M	$-59.24M	$36.76M	$41.08M	$39.30M	$47.91M	$58.44M	$52.04M	$42.41M	$49.21M	$39.01M	$48.60M	$57.19M	$52.98M	$45.27M	$41.50M	$34.97M	$20.82M	$16.89M	$9.70M	$6.18M	$5.04M	$4.53M
Avg Forecast	$7.57M	$7.57M	$7.24M	$7.24M	$1.97M	$1.65M	$1.65M	$5.60M	$88.21M	$76.36M	$59.09M	$96.73M	$85.15M	$72.79M	$65.06M	$69.59M	$50.91M	$34.15M	$37.45M	$42.21M	$26.75M	$16.85M	$19.62M	$13.80M	$11.28M	$13.13M	$13.28M	$11.34M	$9.31M	$4.22M
High Forecast	$7.57M	$7.57M	$7.24M	$7.24M	$1.97M	$1.65M	$1.65M	$5.60M	$88.21M	$76.36M	$59.09M	$96.73M	$85.15M	$72.79M	$65.06M	$69.59M	$50.91M	$34.15M	$37.45M	$42.21M	$26.75M	$16.85M	$19.62M	$16.56M	$13.54M	$15.76M	$15.93M	$13.61M	$11.18M	$5.07M
Low Forecast	$7.57M	$7.57M	$7.24M	$7.24M	$1.97M	$1.65M	$1.65M	$5.60M	$88.21M	$76.36M	$59.09M	$96.73M	$85.15M	$72.79M	$65.06M	$69.59M	$50.91M	$34.15M	$37.45M	$42.21M	$26.75M	$16.85M	$19.62M	$11.04M	$9.02M	$10.51M	$10.62M	$9.07M	$7.45M	$3.38M
Surprise %	-	-	-	-	-	0.97%	-	0.55%	-0.67%	0.48%	0.70%	0.41%	0.56%	0.80%	0.80%	0.61%	0.97%	1.14%	1.30%	1.36%	1.98%	2.69%	2.12%	2.53%	1.85%	1.29%	0.73%	0.54%	0.54%	1.07%

TherapeuticsMD's average Quarter SG&A projection for Dec 23 is $1.97M, based on 1 Wall Street analysts, with a range of $1.97M to $1.97M. The forecast indicates a 24.20% rise compared to TXMD last annual SG&A of $1.59M (Sep 23).

TherapeuticsMD EPS Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	9	9	9	9	5	5	5	12	10	7	11	13	12	10
EPS	-	-	-	-	-	$-0.32	-	$-0.37	$-3.68	$-3.13	$12.83	$-8.34	$-0.12	$-0.11	$-0.11	$-0.11	$-0.15	$-0.12	$-0.19	$-0.21	$-0.19	$-0.13	$-0.23	$-0.16	$-0.11	$-0.11	$-0.11	$-0.13	$-0.06	$-0.06
Avg Forecast	$0.04	$0.04	$0.03	$0.03	$-0.13	$-0.15	$-0.07	$0.06	$-0.57	$-3.04	$-4.00	$-3.83	$-5.00	$-5.50	$-6.13	$-5.30	$-6.71	$-8.31	$-9.51	$-9.23	$-9.42	$-8.64	$-8.33	$-0.18	$-0.09	$-0.11	$-0.07	$-0.07	$-0.06	$-0.04
High Forecast	$0.04	$0.04	$0.03	$0.03	$-0.13	$-0.15	$-0.07	$0.06	$-0.57	$-3.04	$-4.00	$-3.83	$-5.00	$-5.50	$-6.13	$-5.30	$-6.71	$-8.31	$-9.51	$-9.23	$-9.42	$-8.64	$-8.33	$-0.14	$-0.07	$-0.09	$-0.06	$-0.06	$-0.05	$-0.03
Low Forecast	$0.04	$0.04	$0.03	$0.03	$-0.13	$-0.15	$-0.07	$0.06	$-0.57	$-3.04	$-4.00	$-3.83	$-5.00	$-5.50	$-6.13	$-5.30	$-6.71	$-8.31	$-9.51	$-9.23	$-9.42	$-8.64	$-8.33	$-0.22	$-0.11	$-0.13	$-0.08	$-0.08	$-0.07	$-0.05
Surprise %	-	-	-	-	-	2.13%	-	-6.17%	6.46%	1.03%	-3.21%	2.18%	0.02%	0.02%	0.02%	0.02%	0.02%	0.01%	0.02%	0.02%	0.02%	0.02%	0.03%	0.89%	1.22%	1.00%	1.57%	1.86%	1.00%	1.50%

According to 1 Wall Street analysts, TherapeuticsMD's projected average Quarter EPS for Sep 22 is $-3.04, with a low estimate of $-3.04 and a high estimate of $-3.04. This represents a -123.69% decrease compared to TXMD previous annual EPS of $12.83 (Jun 22).

TherapeuticsMD Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
TXMD	TherapeuticsMD	$1.14	$5.00	338.60%	Buy
EVOK	Evoke Pharma	$4.59	$18.00	292.16%	Buy
AQST	Aquestive Therapeutics	$3.85	$10.00	159.74%	Buy
IRWD	Ironwood Pharmaceuticals	$3.53	$8.50	140.79%	Buy
CYTH	Cyclo Therapeutics	$0.66	$0.95	43.94%	Buy
ANIP	ANI Pharmaceuticals	$55.83	$79.00	41.50%	Buy
ORGO	Organogenesis	$3.57	$5.00	40.06%	Buy
ALKS	Alkermes	$30.75	$37.50	21.95%	Hold
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy

TXMD Forecast FAQ

Is TherapeuticsMD a good buy?

Yes, according to 1 Wall Street analysts, TherapeuticsMD (TXMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of TXMD's total ratings.

What are TherapeuticsMD's analysts' financial forecasts?

TXMD's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $9M (high $9M, low $9M), average EBITDA is $-45.65M (high $-37.535M, low $-53.764M), average net income is $-55.518M (high $-44.161M, low $-66.876M), average SG&A $29.62M (high $29.62M, low $29.62M), and average EPS is $0.14 (high $0.14, low $0.14).

Did the TXMD's actual financial results beat the analysts' financial forecasts?

Based on TherapeuticsMD's last annual report (Dec 2023), the company's revenue was $1.3M, which missed the average analysts forecast of $3.3M by -60.55%. Apple's EBITDA was $-6.734M, missing the average prediction of $-38.078M by -82.32%. The company's net income was $-7.699M, missing the average estimation of $-55.661M by -86.17%. Apple's SG&A was $8.9M, missing the average forecast of $10.86M by -18.03%. Lastly, the company's EPS was $-0.74, beating the average prediction of $-0.29 by 155.17%. In terms of the last quarterly report (Sep 2023), TherapeuticsMD's revenue was $-53K, missing the average analysts' forecast of $500K by -110.60%. The company's EBITDA was $-1.284M, beating the average prediction of $-373K by 243.86%. TherapeuticsMD's net income was $-3.378M, beating the average estimation of $-1.73M by 95.28%. The company's SG&A was $1.59M, missing the average forecast of $1.65M by -3.38%. Lastly, the company's EPS was $-0.32, beating the average prediction of $-0.15 by 113.33%